Software is playing a growing role in clinical trials, and over the years it’s been introduced as a tool to help enroll patients, collect data, and analyze results. But one aspect of clinical trial record-keeping has been stubbornly stuck on paper—the reporting of data to the patients who volunteer for the studies. TrialAssure, a Canton, […]

Oncternal Therapeutics has joined the growing ranks of San Diego biotechs to go public, but it didn’t go through an IPO to get there. The San Diego-based company said Monday that it completed a reverse merger with GTx, a Memphis, TN biotech whose market value plummeted last fall after its lead drug candidate failed a […]

We at Xconomy were thrilled to see such a great turnout at our first-ever awards gala in San Diego. About 250 people from the local life sciences community filled a ballroom at Estancia La Jolla Hotel & Spa (see photos above). As Greg Huang, Xconomy’s editor in chief, said in his opening remarks before a […]

Two executives at software company Tealium were recognized Thursday with a regional “Entrepreneur of the Year” award from EY for their leadership of the rapidly growing San Diego-based tech firm, which recently raised $55 million in outside investment. Tealium CEO Jeff Lunsford and Mike Anderson, its founder and CTO, were jointly given the Software category […]

Three wildly different startups among those incubating at EvoNexus, a La Jolla, CA-based nonprofit organization that supports early-stage tech companies, earned top marks from the audience at a pitch contest this week. EvoNexus typically hosts a “Demo Day” event twice per year to highlight the top startups currently housed in its incubator. The event is […]

Veteran Eli Lilly (NYSE: LLY) executive Pete Salzmann has been appointed CEO of Immunovant. Salzmann has spent 20 years at Lilly, most recently as global clinical development leader for baricitinib (Olumiant), the rheumatoid arthritis drug that won FDA approval last year. Immunovant, which splits its operations between New York and Basel, Switzerland, is a subsidiary […]

An Eli Lilly migraine drug that was approved last fall now has the regulatory nod to treat a rarer form of headache that tends to occur in clusters. The FDA on Tuesday approved the Lilly (NYSE: LLY) drug galcanezumab (Emgality) for episodic cluster headaches, which patients experience as one to four headaches per day, each […]

Two weeks after raising $40 million to push ahead with its drug development programs, Inhibrx submitted paperwork to the SEC revealing that it aims to raise money in the public market, too. The La Jolla, CA-based company, which is developing protein drugs targeting cancer and other diseases, was founded in 2010. Read more about the […]